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INTRODUCTION {#s1}
============

Hepatitis B virus infection is a global public health problem. More than 300 million HBV carriers are living worldwide, and approximately 500,000 patients die annually from HBV-related liver disease. Despite the availability of HBV vaccines, the rate of HBV-related hospital admissions, cancers, and deaths in the United States have more than doubled during the past decade.^[@R1]^ According to the reports of World Health Organization (WHO) in 2001 and Centers for Disease Control and Prevention (CDC) in 2005, prevalence of chronic hepatitis B infection ranged between 2-7% in Iran.^[@R2]^ In 1991 WHO recommended universal childhood vaccination. While due to effective mass vaccination of neonates (since 1993), the infection rate in children aged 2-14 years decreased from 1.3% to 0.8% (p \< 0.05) and the number of HBV carriers declined, the average age of infected individuals has increased and the prevalence of HBV is between 2-4% in middle and old aged Iranians.^[@R3]-[@R5]^

Despite these improvements, HBV related morbidity and mortality are high and have more than doubled during the past decade in the United States. In 2010 Institute of Medicine (IOM) had a very important report, which concluded that lack of awareness in public and health providers, led to lack of public resource allocation. At risk people are not aware about infection prevention and may not have access to preventive services. Also, chronically infected patients who are not aware of their disease do not seek medical attention and are not careful about spreading the infection to other people. On the other hand health providers do not screen general population and do not manage diagnosed patients properly. In addition to these facts, there is inadequate access to medical testing, management, and disease surveillance systems.^[@R6]^ All these data led to update on American Association for the Study of Liver Diseases(AASLD) practice guideline, which recommended screening for HBV in populations with intermediate prevalence rates (3-5%).^[@R7]^

Currently indications for HBV screening in health care system of Iran are: blood donors, blood or blood products recipients before 1985, organ transplants recipients before 1985, health care and emergency room workers, after contact with probable HBsAg positive blood, patients undergoing renal dialysis chronically, pregnant women (third trimester), intravenous drug abusers, infants born from HBs Ag positive mothers (9-15 months), patients with signs and symptoms of acute hepatitis, lab data in favor of acute hepatitis (ALT \*5), family screening (first degrees), patients with signs and symptoms of chronic hepatitis, and lab data in favor of chronic hepatitis (ALT \*1.5-2 times).^[@R8]^

Keeping in mind that we have to consider the prevalence of HBV as intermediate in Iranian older than 24 years old, it is acceptable to start active screening of HBV in general population according to 2009 AASLD practice guideline. Fortunately in Iran, there is a good healthcare infrastructure, which is under supervision of the local School of Medicine.^[@R9]^ In Tehran most of health care systems are under supervision of Shahid Beheshti University of Medical Sciences. In 2011, 11812 persons were reported to be HBS Ag positive in Iran, of whom 2515 individuals were from Tehran and 2203 were under supervision of Shahid Beheshti University of Medical Sciences.^[@R10]^ Therefore it seemed feasible to start active screening for HBV in the patients who were visited in the clinics affiliated to the University's health care system and evaluate its effect.

MATERIALS AND METHODS {#s2}
=====================

In 2010 we held three discussion sessions with Shahid Beheshti's health department headquarters. They agreed to collaborate with our center (Gastroenterology and Liver Disease Research Center of Shahid Beheshti University of Medical Science, Tehran, Iran). At the first step we conducted eight seminars for primary health care physicians who worked in the health system. In these seminars we asked them to start active screening for HBsAg in all their patients (with or without risk factors), if they were not screened before. Also a flow chart was introduced to guide them how to check and refer their patients to Taleghani Hospital for further evaluation ([figure 1](#F1){ref-type="fig"}). Ethics Committee of University approved this study. Patients were informed about this study and agreed to pay for the tests.
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Fifteen health care centers (Varamin, Robat Karim, Gharb, Shahriyar, Baharestan, Emam Khomeini, Lavasanat, Shabani, Shemiranat, Shargh, Pakdasht, Ferdosieh, Shomal Gharb, Besat) contributed. From each health center two primary health care physicians were selected to participate in this program. They attended in monthly educational hepatitis classes to be trained as viral hepatitis focal points.

Patients who were referred to Taleghani Hospital were at first registered and then our researchers completed a detailed data collection form for them. In the forms we asked them about their martial statues, family history, possible routes of transmission, and the related signs and symptoms. Also our researchers educated the patients about chronic HBV disease, its course and complications, proper life style, transmission prevention methods, and family screening. Then the patients were referred for blood sampling and the samples were sent to the laboratory for required tests (AST, ALT, HBV DNA PCR quantitative, HBc Ab IgG, HBeAg, and HBeAb). Thereafter the patients were referred to the hepatitis clinic (with results of lab tests and abdominal ultrasonography) to consult with a hepatologist. During this visit for each patient, the phase of chronic HBV infection was determined ([table 1](#T1){ref-type="table"}), and appropriate management (according to the guidelines) was started.

###### Phase of HBV infection^[@R11]^

  --------------------------------------------- ---------------------- -------------------------------------- ----------
  **Phases of chronic Hepatitis B infection**                                                                 
  **Phase**                                     **HBeAg**              **HBV DNA**                            **ALT**
  Immune tolerant                               Positive               Very high \>20,000 IU/mL               Normal
  Immune active                                 Positive or Negative   \>2000 IU/mL Usually \> 20,000 IU/mL   Elevated
  Inactive                                      Negative               \<2000 IU/mL                           Normal
  --------------------------------------------- ---------------------- -------------------------------------- ----------

In 2015 further sub classification for chronic HBV infection phases, especially HBeAg negative patients was suggested by Anna Lok ([table 2](#T2){ref-type="table"}). A second analysis was performed using this classification.

###### Definitions of Phase of chronic HBV infection^[@R12]^

  -------------------------- ------------------------ -------------------------- ---------------------
                                                      **HBV DNA level, IU/mL**   **ALT level, ULNa**

  HBeAg- positive patients   Immune tolerance phase   ≥ 20,000                   \<ULN

                             Mildly active phase      ≥ 20,000                   1-2 × ULN

                             Immune active phase      ≥ 20,000                   \> 2 × ULN

                             Low replication phase    \<20,000                   Any level of ALT

  HBeAg -negative patients   Inactive carrier phase   \< 2000                    \<ULN

                             Indeterminate phase      \< 2000\                   \>ULN\
                                                      \> 2000                    \<ULN

                             Mildly active phase      ≥ 20,000                   1-2 × ULN

                             Immune active phase      ≥ 20,000                   \> 2 × ULN
  -------------------------- ------------------------ -------------------------- ---------------------

^a^ULN (upper limit of normal) for ALT is according to the traditional cut-off value of 40 U/L

A value of 40 U/L was used to define the upper limit of normal (ULN) for ALT. A second analysis was performed with an ULN of ALT of 19 for women and 30 for men.

Obtained data were transferred into SPSS software version 21 (SPSS, Inc, Chicago, IL) for analyses.

RESULTS {#s3}
=======

In 2011 (before initiation of active screening), 94 patients were referred from health centers to Taleghani Hospital for further management. Sixty nine of these patients were new cases. In 2012 (after initiation of active screening) this number increased to 333, of whom 203 were newly diagnosed cases.

In 2011, family screening was performed for 300 persons, of whom 42 were HBsAg positive, while 38 had cleared the disease and successful vaccination was done only for 12 persons. In 2012, family screening was performed for 616 family members and 48 new cases were found, while 434 individuals needed vaccination ([figure 2](#F2){ref-type="fig"}).
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Totally in 2011 and 2012, 427 HBsAg positive patients were referred to Taleghani Hospital and 90 more patients were diagnosed by family screening. The mean age of the patients was 39.1±15.1 years (ranged from 5 to 85 years old) and 51.5% of them were men while 48.5% were women. HBeAg was positive in 71 (13.7 %) patients. In HBeAg positive cases, seven patients were in immune tolerant and five were in immune active phases when a value of 40 U/L was used to define the ULN, but when we used the value of 30 U/L for men and 19 U/L for women these numbers where 4 and 15 respectively. Most of these changes were in female patients (7 out of 10). Other HBeAg positive patients did not fulfilled the criteria of each phase and could not be classified. In HBeAg negative cases, 10 patients were classified as immune active with ALT upper limit of 40 U/L, but this number increased to 22 when we used the values of 30U/L for men and 19 U/L for women.

By using the new classification, the patients were more precisely classified ([table 3](#T3){ref-type="table"}).

###### Frequency of HBV Phase in referred patients

  -------------------------- ------------------------ --------------------------------------- ------------------------------------------------------ -------- --------
                                                      **ALT cut-off value of 40 U/L IU/mL**   **ALT cut-off value of 30 & 19 U/L for men & women**            
  HBeAg- positive patients   Immune tolerance phase   6                                       1.16%                                                  4        0.77%
  Mildly active phase        2                        0.38%                                   3                                                      0.58%    
  Immune active phase        0                        0                                       1                                                      0.195%   
  Low replication phase      63                       12.18%                                  63                                                     12.18%   
  Total                      71                       13.73%                                  71                                                     13.73%   
  HBeAg -negative patients   Inactive carrier phase   365                                     70.59%                                                 285      55.12%
  Indeterminate phase        57                       11.02%                                  132                                                    25.53%   
  Mildly active phase        23                       4.44%                                   27                                                     5.22%    
  Immune active phase        1                        0.195%                                  2                                                      0.38%    
  Total                      446                      86.26%                                  446                                                    86.26%   
  Overall                    517                      100%                                    517                                                    100%     
  -------------------------- ------------------------ --------------------------------------- ------------------------------------------------------ -------- --------

DISCUSSION {#s4}
==========

Historically, health services in the western world are based on providers and policy makers understanding of the population health status. The optimal model of care dictates that services meet the genuine health needs of the general population. Data on community incidence, prevalence of disease, and the effectiveness of interventions form the traditional method of determining need. In comparative approach, the services provided for a defined population contrasts with those elsewhere or within the same population over time, and therefore may accelerate the achievement of equity in health planning.^[@R13]^

Good quality means providing patients with appropriate services in a technically adequate method, by good communication, shared decision making, and cultural understanding. Too much care (e.g., providing unnecessary tests, medications, and procedures, with associated risks and side effects), too little care (e.g., not providing an indicated diagnostic test or a lifesaving surgical procedure), or the wrong care (e.g., prescribing medicines that should not be given together, using poor surgical technique) are practical examples of poor quality.^[@R14]^

The Alma Ata declaration^[@R15]^ highlighted the importance of primary care, and many countries including Iran revised their healthcare system to meet the global aim of 'Health for All' by 2000. There is a good healthcare system in Iran,^[@R9]^ and as it can be seen in the

ure 3, president of medical university in every province has the highest health authority in the area and is in charge of public health.

This network consists of a referral system, starting at primary care centers (in the periphery), going through secondary-level hospitals in the provincial capital and tertiary hospitals in major cities.^[@R16]^

In 2010, report of Institute of Medicine (IOM) concluded that lack of awareness in public and health providers resulted in inadequate preventive means, disease surveillance, and screening systems and consequently inappropriate management of infected patients. As the consequence, morbidity and mortality related to HBV is high and even have more than doubled during the past decade in the United States.^[@R6]^ All these data led to update on AASLD practice guideline, which recommended screening for HBV in populations with intermediate prevalence rates (3-5%).^[@R7]^ Keeping in mind that the prevalence of HBV is between 2-4% in middle and old aged Iranian population,^[@R3]-[@R5]^ it seems appropriate to start HBV screening for them. At present indications for HBV screening in health care system of Iran are just for high-risk individuals.^[@R8]^ According to these criteria, 2189 individuals were screened by heath system in 2011 and 2372 persons were screened in 2012 (after implementation of this program) ([table 4](#T4){ref-type="table"}).

###### Frequency of HBV positive patients in high risk groups according to Health Department of Shahid Beheshti University of Medical Sciences reports^[@R10],[@R17]^

  ------------------------- ---------- ----------
  **Screening groups**      **2011**   **2012**
  IV drug abusers           238        158
  Family members            43         97
  Blood or blood products   35         32
  Unprotected Sex           5          16
  Pregnancy                 164        243
  Hemodialysis              11         7
  Others                    1693       1819
  Total                     2189       2372
  ------------------------- ---------- ----------

This increase in case finding, even in high-risk groups (especially pregnant women and family members of HBV positive patients), demonstrates that screening is suboptimal and needs reinforcement. Also we have to keep in mind that many of HBsAg positive patients have no signs and symptoms and specially middle and old aged patients are not in high risk groups so more intensive screening seems appropriate for these patients. In 2011 (before initiation of active screening), 94 patients were referred from health centers to Taleghani Hospital for further management. Sixty nine of these patients were new cases. In 2012 (after initiation of active screening) this number increased to 333, of whom 203 were newly founded cases.

Another point is that recognized HBV positive patients and their families are not managed appropriately in the present health system. Family screening was done on 300 and 616 first degree family members of the referred patients in 2011 and 2012, and 42 and 48 new cases were found respectively ([figure 3](#F3){ref-type="fig"}). Although anti HBV vaccination was done for 80 family members in 2012 and has increased considerably compared with 2011 which was only 12 persons (probably due to the better education of primary care physicians), It is noteworthy to perpend that 220 and 434 of these family members were at risk of HBV infection and needed vaccination in 2011 and 2012 respectively ([figure 1](#F1){ref-type="fig"}). These data confirm the need for hepatic centers in health system and closer collaboration of health system with tertiary therapeutic centers to refer the diagnosed patients for proper management. The proposed algorithm ([figure 1](#F1){ref-type="fig"}) fills this gap.

Implementation of this program has economic burden on health system. Financial long term benefits of early disease detection, management, and prevention of complications should be assessed against the increased cost of screening in another study. We suggest similar pilot studies in other parts of the country. We also suggest preparation of short guidelines and algorithms for referral of patient to secondary and tertiary centers and also more education for health care providers such as physicians, and nurses for more cost effective strategies for screening, evaluation, and management of these patients.

Although health system is active about screening of HBV infection in high risk populations, it is not perfect. There is no specific clinic for patients with HBV in health system. Primary health care physicians need more education about referring protocols. We propose that health system needs to upgrade the screening and management programs of HBV infection. We also propose active HBV screening for people more than 20 years old who have not been vaccinated in the national vaccination programs and never been tested for HBV before.
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